Anebulo Pharmaceuticals, Inc. earnings releases ANEB

Annual Quarterly

Anebulo Pharmaceuticals, Inc. last reported quarterly results on Feb 12, 2026, for Q2 FY2026 (the quarter ended Dec 31, 2025): diluted EPS of -$0.05. It usually reports 43–45 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 43–45 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Feb 12, 2026 43 days after quarter end	Q2 FY2026 ended Dec 31, 2025	—	-2 +18.8%	-0.05 +44.4%
Nov 13, 2025 44 days after quarter end	Q1 FY2026 ended Sep 30, 2025	—	-2 +1.9%	-0.05 +37.5%
May 13, 2025 43 days after quarter end	Q3 FY2025 ended Mar 31, 2025	—	-2 -1.4%	-0.04 +33.3%
Feb 14, 2025 45 days after quarter end	Q2 FY2025 ended Dec 31, 2024	—	-2 +9.4%	-0.09 +18.2%
Nov 13, 2024 44 days after quarter end	Q1 FY2025 ended Sep 30, 2024	—	-2 +11.3%	-0.08 +20.0%
May 15, 2024 45 days after quarter end	Q3 FY2024 ended Mar 31, 2024	—	-2 +40.9%	-0.06
Feb 13, 2024 44 days after quarter end	— ended Dec 31, 2023	—	—	—
Nov 14, 2023 45 days after quarter end	— ended Sep 30, 2023	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ANEB (OTC)
Fiscal year ends: June 30
Incorporated in: DE
Headquarters: Lakeway, TX
SEC filer status: Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK: 1815974

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.